- Home
- DHF vs FENC Comparison
DHF vs FENC Comparison
Compare DHF & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHF
- FENC
- Stock Information
- Founded
- DHF 1998
- FENC 1996
- Country
- DHF United States
- FENC United States
- Employees
- DHF N/A
- FENC N/A
- Industry
- DHF Finance Companies
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHF Finance
- FENC Health Care
- Exchange
- DHF Nasdaq
- FENC Nasdaq
- Market Cap
- DHF 188.4M
- FENC 172.8M
- IPO Year
- DHF N/A
- FENC 2001
- Fundamental
- Price
- DHF $2.58
- FENC $5.92
- Analyst Decision
- DHF
- FENC Strong Buy
- Analyst Count
- DHF 0
- FENC 2
- Target Price
- DHF N/A
- FENC $14.00
- AVG Volume (30 Days)
- DHF 451.1K
- FENC 81.3K
- Earning Date
- DHF 01-01-0001
- FENC 11-07-2024
- Dividend Yield
- DHF 7.65%
- FENC N/A
- EPS Growth
- DHF N/A
- FENC N/A
- EPS
- DHF N/A
- FENC N/A
- Revenue
- DHF N/A
- FENC $49,348,000.00
- Revenue This Year
- DHF N/A
- FENC $107.12
- Revenue Next Year
- DHF N/A
- FENC $33.37
- P/E Ratio
- DHF N/A
- FENC N/A
- Revenue Growth
- DHF N/A
- FENC 278.09
- 52 Week Low
- DHF $2.06
- FENC $3.96
- 52 Week High
- DHF $2.39
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- DHF 46.74
- FENC 51.81
- Support Level
- DHF $2.53
- FENC $6.00
- Resistance Level
- DHF $2.62
- FENC $6.36
- Average True Range (ATR)
- DHF 0.03
- FENC 0.30
- MACD
- DHF 0.00
- FENC -0.06
- Stochastic Oscillator
- DHF 55.00
- FENC 47.37
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.